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OBJECTIVE: The aim of this study was to determine the efficacy of 252Californium neutron intracavitary
brachytherapy using a two-channel Y applicator combined with external beam radiotherapy for the treatment
of endometrial cancer.
METHODS: Thirty-one patients with stage I–III endometrial cancer were recruited for this study. The stage I
patients received only 252Californium neutron intracavitary brachytherapy with a two-channel applicator. The
stage II and III patients received both 252Californium neutron intracavitary brachytherapy using a two-channel
applicator and parallel-opposed whole pelvic radiotherapy.
RESULTS: The five-year local control rate was 80.6% (25/31), the overall survival rate was 51.6% (16/31), and the
disease-free survival rate was 54.8% (17/31). The incidence of serious late complications was 12.9% (4/31).
CONCLUSIONS: 252Californium neutron intracavitary brachytherapy using a two-channel applicator combined
with external beam radiotherapy was effective for treating endometrial cancer and the incidence of serious late
complications related to this combination was within an acceptable range.
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’ INTRODUCTION
Endometrial cancer is one of the most common gyneco-
logic malignancies worldwide. According to a report from the
American Cancer Society, approximately 52,630 new cases of
endometrial cancer were diagnosed and 8,590 deaths were
associated with endometrial cancer in the United States in 2014
(1). The National Cancer Institute of China estimated that there
would be 47,751 new cases of endometrial cancer in China in
2010 (2). Currently, surgery remains the standard treatment for
early-stage endometrial cancer. However, radiation has become
a more suitable treatment option for patients with medically
inoperable endometrial cancer or for those of advanced age.
In terms of a definitive radiotherapy for endometrial cancer,
intracavitary brachytherapy (ICBT) alone can be used to treat
stage I patients. Moreover, ICBT combined with external beam
radiotherapy (EBRT) can be used to treat patients with local
advanced-stage endometrial cancer. Generally, there are two
types of brachytherapy using conventional g-rays: high-dose-rate
(HDR) brachytherapy using 192Ir or low-dose-rate (LDR)
brachytherapy using 137Cs. There have been no randomized
controlled trials (RCT) comparing the effects of HDR bra-
chytherapy and LDR brachytherapy on endometrial cancer
in recent years because endometrial cancer is rarely treated
with radiotherapy alone (3,4).
Many reports in the literature have described the use of
californium-252 (252Cf) as a neutron source for the treatment
of cervical cancer due to its higher relative biologic effectiveness
(RBE) and lower oxygen enhancement rate (OER) than g-rays
(5,6). Moreover, the 252Cf neutron source has been used
effectively for ICBT of endometrial cancer (7). However, a
single-channel applicator was used in most endometrial cancer
studies (8,9), including our own, which is described below (10).
The use of a single-channel applicator has several drawbacks,
including longer treatment durations and a slightly higher
incidence of complications than the use of a two-channel
applicator (9). Further, the dose distribution associated with a
single-channel applicator is not ideal and is difficult to adjust.
Between 1999 and 2004, our center performed 252Cf neutronDOI: 10.6061/clinics/2016(01)03
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ICBT using a single-channel applicator to treat 40 cases of
endometrial cancer and we observed the above-described
shortcomings associated with this method (i.e., long treatment
durations, a high rate of complications and difficulty in
adjusting the dose and the dose distribution).
The modification of two-channel (TC) Y (Rotte Y)
applicators for brachytherapy has overcome many of the
shortcomings associated with single-channel applicators,
particularly with regard to adjustment of the optimal dose
distribution in the craniocaudal and lateral directions.
Therefore, TC applicators have become the standard fixed
applicators used for g-ray ICBT of endometrial cancer (11).
In 2007, our center began employing a 252Cf neutron
source using the TC applicator for endometrial cancer
treatment. The aim of this study was to assess the clinical
outcomes of endometrial cancer patients treated via 252Cf
neutron ICBT using a TC applicator combined with EBRT.
’ MATERIALS AND METHODS
Subjects
Thirty-one stage I–III endometrial cancer patients diag-
nosed based on biopsy findings and staged according to the
International Federation of Gynecology and Obstetrics
(FIGO) guidelines from September 2007 to August 2011
were included in this study. Among these patients, the most
common comorbidities associated with receiving radiother-
apy alone included hypertension and diabetes (Table 1).
None of the patients had received treatment before the study,
and all endometrial cancer diagnoses had been confirmed by
histology. All of the patients exhibited Karnofsky scores
greater than 70 and hemoglobin levels greater than 90 g/L;
their mean age was 55.9 years (range: 30–72 years) (Table 1).
All of the patients underwent a chest x-ray, an abdominal
B-ultrasound, a pelvic CT or MRI, cystoscopy and a colo-
noscopy as components of their pre-treatment evaluation.
During the course of treatment, a pelvic B-ultrasound and
a gynecological examination were performed every week
to examine changes in uterine size and uterine cavity
depth.
Treatment methods
Equipment. An LZH-1000 252Cf neutron brachytherapy
machine (Shenzhen Lingdun Technology, Shenzhen, China)
and an 8 MV/X linear accelerator (Elekta Corp., Stockholm,
Sweden) were used. For the 252Cf neutron source, the average
energy was 2.3 MeV, with a half-life of 2.645 years; the shape
was cylindrical with dimensions of 3 mm in diameter  8 mm
in height, an active region of 1.4 mm  9.0 mm, and a source
strength per unit volume of 500–200 mg. The following
formula was used to calculate the 252Cf dose: equivalent
biological dose (DGY-eq) = neutron relative biological
effectiveness (RBE) of 252Cf  252Cf neutron dose + g-ray
RBE x g-ray dose; the 252Cf RBE ranged from between 4–6.
Treatment plan. Stage I patients underwent 252Cf
neutron ICBT using the TC applicator alone. Stage II or III
patients underwent 252Cf neutron ICBT using the TC
applicator combined with EBRT. All patients were hospita-
lized throughout the treatment period. External radiation
was applied four times per week with opposing fields and
a dose per fraction of 2 Gy. Once the total dose reached
20–36 Gy in 10–18 fractions, the central portion of the field
was shielded using a 4 cm thick lead block, and the treatment
was continued with antero-posterior field irradiation until
the total dose reached 46–50 Gy. 252Cf neutron ICBTusing the
TC applicator was delivered after 4–5 fractions of EBRT.
ICBT then continued once per week, with the EBRT applied
on 4 other days of the week. The total treatment duration
was 6-7 weeks. A non-steroidal painkiller or morphine was
administered before applicator placement. Barium enemas
and bladder catheterizations were prepared prior to injection
of the contrast agent into the balloon. Then, between 7 and
12 cervical dilatation rods were used sequentially to grad-
ually expand the cervix until it was sufficiently enlarged. The
two channels of the applicator were turned to a vertical
position such that the two front ends were closed together,
followed by insertion of the fundus was inserted into the
uterus. The TC applicator was then turned to the horizontal
position such that the top of the two channels reached the
two horns of the uterus, and an anterolateral image was
captured (Figure 1). Points A and F (point F was defined on
line A, 2 cm lateral to the top of the TC applicator) were
chosen as the dose reference points. The brachytherapy dose
was 40–45 Gy to point A and 48–55 Gy to point F in 4–5
fractions. For stage I patients, the dose at point F was higher
than that at point A. For stage II or III patients, the dose at
point F was approximately the same as that at point A
(Figure 2). The dose at the posterior wall of the bladder and
the rectum was adjusted based on the isodose contour so that
the dose at the bladder and the rectum was below 80% of
that at point A. Stage I or II patients were administered a
single channel and a vault tube of internal irradiation
(Figure 3) to supplement potentially insufficient doses at
the uterine fundus and the vaginal fornix. The ratio of the
Table 1 - Patient characteristics.
Characteristics Number of patients (%)*
Total number of patients 31
Age (y)
30–50 5 (16.0%)
51–60 18 (58.0%)
61–72 8 (26.0%)
Mean 55.9
BMI (kg/m2)
Mean 27
Range 20–41
Stage (FIGO)
I 5 (16.0%)
II 22 (71.0%)
III 4 (13.0%)
Morphology
Adenocarcinoma 28 (90.0%)
Clear cell carcinoma 3 (10.0%)
Histopathologic grade
1 11 (35.5%)
2 13 (41.9%)
3 5 (16.1%)
Unknown 2 (6.5%)
Comorbid diseases
Hypertension 11 (35.5%)
Diabetes 11 (35.5%)
Coronary artery disease 3 (9.7%)
Systemic lupus erythematosus 2 (6.4%)
Others** 4 (12.9%)
* Thirty-one patients were enrolled in the study.
**Others included refusal of surgery or severe chronic obstructive
pulmonary disease.
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dose applied to the cervix to the dose applied to the vaginal
fornix was 1.0:(0.8–1.0) for stage I patients (Figure 4) and 1.0:
(1.2–1.4) for stage II patients (Figure 5). During 252Cf neutron
ICBT using the TC applicator, the patients were monitored
for symptom alleviation, and gynecological examinations
were performed weekly to determine the size of the uterus
and the extent of tumor regression. At six months post-
treatment, uterine curettage and histopathological examina-
tion were performed to examine tumor cell regression.
Follow-ups. Beginning one month post-treatment, a
pelvic B-ultrasound was performed monthly. At three months
post-treatment, uterine curettage and histopathological exam-
ination of the endometrial tissues were performed. Outpatient
follow-up visits were required once every three months
beginning three months post-treatment and once every six
months beginning one year post-treatment. None of the
patients were lost to follow-up.
Figure 1 - A) Antero-posterior view; B) anterolateral view. The anterolateral image was captured when the TC applicator was turned to
the horizontal position; this image shows that the top of the two channels reached the two horns of the uterus. A and F denote dose
reference points A and F, respectively. The cervix is indicated by arrows, and the uterus is indicated by curled arrows.
Figure 2 - Isodose contour showing that the dose at point F was
nearly identical to that at point A in stage II and III patients.
A and F denote dose reference points A and F, respectively. The
cervix is indicated by arrows and the uterus is indicated by curled
arrows.
Figure 3 - Image showing the method by which stage I and II
endometrial cancer patients were administered a single channel
and a vault tube of internal irradiation to supplement poten-
tially insufficient doses at the uterine fundus and the vaginal
fornix. A and F denote dose reference points A and F, res-
pectively. The cervix is indicated by arrows, and the uterus is
indicated by curled arrows.
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Statistical analysis. SPSS13.0 software was used for
statistical analyses. Discrete data are presented as frequencies
(percentages); continuous data are presented as means± SE.
For statistical analyses, Chi-square contingency table analysis
and Kaplan-Meier tests were performed; p-valueso0.05 were
considered statistically significant (Tables 2 and 3).
Ethics. This study was approved by the ethics committee
of our hospital, and all patients signed informed consent
forms.
’ RESULTS
The mean follow-up duration was 54.8 months. Of the
31 patients enrolled in this study, 15 patients died during the
follow-up period. One of the stage I patients died as a result
of fatal coronary artery disease. Two stage III patients died
from the persistent tumor. Three deceased patients had
pelvic lymph node recurrence, four deceased patients had
local recurrence at the time of death, and five deceased
patients had distant metastases. The mean overall survival
duration was 61.8±5.2 months, with a 95% confidence
interval of 51.6–72.0 months (Table 3). The 5-year overall
survival rate for all patients was 51.6% (Figure 6). The
disease-specific survival (DSS) rates for stages I, II, and III
were 100%, 54.5%, and 0%, respectively (Table 2).
Following treatment via 252Cf neutron ICBT using the TC
applicator combined with EBRT, both pelvic B-ultrasound
and gynecological examination showed that the uterus had
shrunk substantially in all 31 patients and that the uterine
cavity depth was reduced to a varying extent (0.5–5.0 cm). Of
the two locally uncontrolled patients treated with an
additional fraction of 252Cf neutron ICBT using the TC
applicator, one experienced locally controlled disease, and
the other, who showed clear cell histology, experienced local
failure. The most common locations of disease recurrence
were distant (16.1%), local recurrence alone (12.9%), and
pelvic lymph nodes (9.6%). Of the five patients with distant
tumor recurrence, three exhibited a single distant tumor
involving the lungs and bone, and two exhibited multi-organ
involvement. Additionally, patients with comorbid endome-
trial cancer and diabetes were more susceptible to metastasis
development and disease recurrence (8/31) (Table 4).
All patients completed the treatment without interruption.
All of the late complications were limited to grade 2, and
there were no recto-vaginal or vesico-vaginal fistulas. Three
patients had frequent urination, urgency, and hematuria at
26 months post-radiotherapy. Cystoscopic examination ruled
out other diseases, and these patients were diagnosed with
radiation cystitis. Another patient was diagnosed with
radiation proctitis. The incidence of late complications was
12.9% (4/31) (Table 5).
’ DISCUSSION
Surgery remains the primary standard treatment for
patients with endometrial cancer. Definitive radiotherapy is
typically offered to patients who suffer from medical
comorbidities and those who have locally advanced tumors,
as surgery may be not suitable for these patients. Therefore,
patients treated via radiotherapy have a higher mortality rate
than those treated via surgery. Nevertheless, radiotherapy
remains the best option for patients with inoperable
endometrial cancer. Thus, comparisons of survival between
surgery and radiotherapy alone are of limited value. Patients
with inoperable endometrial cancer are generally treated via
ICBT alone or in combination with EBRT.
Figure 5 - Isodose contour showing that the ratio of the
dose applied to the cervix to the dose applied to the vaginal
fornix was 1.0:(1.2–1.4) in stage II patients. A and F denote
dose reference points A and F, respectively. The cervix is
indicated by arrows, and the uterus is indicated by curled
arrows.
Figure 4 - Isodose contour showing that the ratio of the
dose applied to the cervix to the dose applied to the vaginal
fornix was 1.0:(0.8–1.0) in stage I patients. A and F denote
dose reference points A and F, respectively. The cervix is
indicated by arrows, and the uterus is indicated by curled
arrows.
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The most common histological type of endometrial cancer
is adenocarcinoma, which is not as sensitive to conventional
radiation as squamous cell carcinoma. Moreover, locally
advanced stage endometrial tumors are often bulky and
contain many hypoxic cells, which are resistant to conven-
tional radiation. In contrast to conventional radioisotopes,
the 252Cf neutron represents a high linear energy transfer
(LET) ray with distinct radiation and biological character-
istics. For example, the 252Cf neutron can cause greater direct
damage to tumor cell DNA, leading to a higher rate of DNA
double-strand breaks, than conventional photon radiation.
The 252Cf neutron also has a higher RBE and a lower OER
than photons (7). Thus, bulky endometrial adenocarcinoma
cells may be particularly sensitive to 252Cf neutrons, and this
form of radiotherapy could be used to treat endometrial
adenocarcinoma patients.
However, 252Cf neutron ICBT has not been the main
method of choice for endometrial cancer because the neutron
source used for ICBT is large and expensive and because it is
difficult to achieve precise biological equivalent dose
calibration using conventional g-rays. Thus, 192Ir and 137Cs
ICBT are the most commonly used forms of ICBTworldwide,
especially in Western Europe and North America. Moreover,
the 252Cf neutron source used for ICBT was a neutron TC
applicator that was larger than the g-ray TC applicator.
Dilatation of the cervix and the uterus is required to insert
the TC applicator. In general, all of the endometrial cancer
patients in our study tolerated TC applicator implantation
well. Patients with late toxicity to radiotherapy in our study
had grade 2 complications and were diagnosed with
radiation proctitis or radiation cystitis.
Patients with locally advanced stage endometrial adeno-
carcinoma or with inoperable endometrial adenocarcinoma
who are treated via a combination of g-ray ICBT and EBRT
often suffer from local-regional relapse. In the past two
decades, the local control rate for patients with locally
advanced stage endometrial adenocarcinoma has remained
unsatisfactory, even when a salvage radical hysterectomy
was performed. The local control rate was 76–84% for stage
I–III endometrial adenocarcinoma patients treated via a
combination of g-ray ICBT and EBRT. Alternatively, 252Cf
neutron ICBT has been found to be effective as a radio-
therapy and to have radiobiological advantages for the
treatment of radio-resistant advanced or bulky endometrial
Table 2 - Outcomes of endometrial cancer treated via 252Cf neutron intracavitary brachytherapy.
Stage No. LCR OS DSS Late toxicity
I 5 100% (5/5) 80.0% (4/5) 100% (5/5) 0% (0/5)
II 22 81.8% (18/22) 54.5% (12/22) 54.5% (12/22) 18.2% (4/22)
III 4 50.0% (2/4) 0% (0/4) 0% (0/4) 0% (0/4)
Total 31 80.6% (25/31) 51.6% (16/31) 54.8% (17/31) 12.9% (4/31)
X2 3.026 5.510 8.496 0.961
P 0.066 0.037 0.004 0.378
No.: number of patients; LCR: local control rate; OS: overall survival; DSS: disease-specific survival.
Table 3 - Overall survival duration of endometrial cancer
patients receiving 252Cf neutron intracavitary brachytherapy.
FIGO stage Mean±SE 95% CI Median±SE 95% CI
I 72.0±2.7 (66.7,77.3)
II 66.5±5.4 (56.0,77.0) 85.0±13.1 (59.4, 110.6)
III 15.3±6.0 (3.50, 27.0) 6.00±7.50 (0.00, 20.8)
Total 61.8±5.2 (51.6, 72.0 73.0±6.79 (59.9, 86.1)
SE: standard error; CI: confidential interval.
Mean overall survival duration=61.8±5.2 months (95% confidence
interval, 5–85 months), X2=31.0, and p=0.000.
Figure 6 - Survival curves of patients with different stages of
endometrial cancer.
Table 4 - The relationships of morphology and comorbid diseases with metastasis development and disease recurrence.
Site Number Morphology Number Comorbid diseases Number
Local recurrence alone 4 (12.9%) Adenocarcinoma 4 (12.9%) Hypertension Diabetes 2 (6.4%) 2 (6.4%)
Pelvic lymph node 3 (9.6%) Adenocarcinoma 3 (9.6%) Diabetes COPD 2 (6.4%) 1 (3.2%)
Persistent 2 (6.4%) Adenocarcinoma Clear cell carcinoma 1 (3.2%) 1 (3.2%) Diabetes 2 (6.4%)
Distant 5 (16.1%)
Lung 2 (6.4%) Adenocarcinoma 2 (6.4%) Hypertension Diabetes 1 (3.2%) 1 (3.2%)
Multi-organ 2 (6.4%) Adenocarcinoma 2 (6.4%) Hypertension SLE 1 (3.2%) 1 (3.2%)
Bone 1 (3.2%) Adenocarcinoma 1 (3.2%) Diabetes 1 (3.2%)
COPD: chronic obstructive pulmonary disease; SLE: systemic lupus erythematosus.
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tumors (7). Our data showed that the local control rate for
stage I–III endometrial adenocarcinoma patients was 80.6%.
However, the local relapse rate of patients with stage I–II
disease was 14.8% (4/27), and that of patients with stage III
disease was 50%.
The selection of an applicator is also important for ICBT of
endometrial adenocarcinoma. The TC ‘‘Y’’ applicator consists
of two rigid applicators, which can reach the two uterine
horns, permitting coverage of a greater uterine width than a
single-channel applicator. The dose distribution of the TC
applicator was more optimal than that of the single-channel
applicator, such that a satisfactory local control rate might
be more effectively achieved using the TC for ICBT of
endometrial adenocarcinoma. However, few studies have
examined the application of the ‘‘Y’’ applicator for treating
endometrial cancer. Ohkubo et al. reported a satisfactory
local control rate in ten patients with stage I–II endometrial
cancer, none of whom suffered from local recurrence at five
years (12). The same TC applicator was used by Coon et al. to
treat 49 endometrial cancer patients (most of whom had
stage I disease) via HDR ICBT; in that study, three patients
(6.1%) experienced local failure and the median time to
disease recurrence was 17 months. These two studies
showing low rates of local recurrence further show that the
radiation doses were sufficient for destroying the tumor in
the uterus.
Differences in tumor stages and differential tumor
grades are associated with distinct outcomes of endome-
trial cancer patients. Without question, higher tumor
stage, lower differential tumor grade, and unfavorable
tumor histological type are associated with poorer prog-
nosis. Previous studies had shown that the five-year
overall survival rates of stage I–III endometrial cancer
patients treated via either 137Cs or 192Ir ICBT, with or
without EBRT 1-5(9,13-16). In contrast, in the study by
Maruyama et al., 252Cf neutron ICBT combined with EBRT
and hysterectomy resulted in five-year overall survival rates
of 83% for stage I, 37% for stage II, and 50% for stage III
endometrial cancer patients (7). Our current data showed a
five-year overall survival rate of 51.6%; this result is consistent
with other results of LDR and HDR studies, although
it is lower than that from the study by Maruyama et al.
We speculate that the primary reason for the higher survival
rate in the study by Maruyama et al. was that nearly half
of the patients (14/31) in that study underwent a
hysterectomy after receiving radiation therapy; the survival
rate of 50% for stage III patients in that study was much
higher than that in a previous report, which showed a
survival rate of only 17.5% among those undergoing
radiotherapy alone (17).
Treatment via 252Cf neutron ICBT combined with EBRT as
performed in our study may be sufficient for patients with
stage I–II endometrial cancer, as these patients showed a
five-year overall survival rate of 59.3%. This survival rate
is comparable to previous reports showing overall
survival rates of 42–61% for stage I–II endometrial cancer
patients (18-21). Our treatment outcomes for the four
patients with stage III endometrial cancer showed an
unsatisfactory mean survival duration of 15.3±6.0
months. Two stage III patients died with persistent
tumors. Regarding the other two stage III patients, one
died 20 months post-treatment due to lung metastasis,
and the other exhibited pelvic lymph node recurrence at
30 months of follow-up. These findings suggest that
alternative treatment strategies should be used for
patients with stage III endometrial cancer.
In the course of using the ‘‘Y’’ applicator to treat
endometrial cancer, two ovoids or a ring applicator and a
single-channel applicator should be added to supplement the
radiation dose to the vaginal vault; such a treatment
generally increases the radiation dose to the bladder and
the rectum. In fact, we observed late toxicity of grade 2 in
12.9% (4/31) of the patients; this frequency is similar to the
results from most studies of stage I–III patients (Table 6).
However, a study of 36 stage I patients by Nguyen et al.
using one tandem and one ovoid or cylindrical applicator to
perform HDR ICBT alone showed a frequency of late toxicity
of up to 21% 6(22).
Although much effort has been invested to identify
more effective methods for ICBT of endometrial cancer,
no completely satisfactory method has been established.
Our retrospective study contains several limitations,
including the accuracy of cancer diagnosis and staging,
the socioeconomic status of the patients, advances in
treatment, and nurse-led supportive care. In particular,
we used 2-D treatment planning, which is not as effec-
tive as 3-D planning for reducing the dose to at-risk
organs (23).
252Cf neutron ICBT using a TC applicator combined with
EBRT is effective for the treatment of endometrial cancer, and
the incidence of serious late complications related to this
therapy is acceptable.
Table 6 - Literature review of the outcomes of inoperable stage I-IV endometrial cancer patients receiving radiotherapy.
Authors Method Number Stage Applicator Local recurrence (%) OS (%) Late toxicity (%)
Inciura, et al. (16) HDRB +/- EBRT 29 I–III Three-channel 17.2 (4/29) 48.3 (5 y) 13.8 (4/29)
Rouanet, et al. (24) LDRB +/- EBRT 147 I–III — 24 (36/147) 58.4 (5 y) 11.7
Knocke, et al. (9) HDRB +/- EBRT 280 I–III One-channel 22.9 (64/280) 52.7 (5 y) 23.9
Churn and Jone (8) HDRB +/- EBRT 37 I-II One-channel 16 (6/37) 68.4 (5 y) —
III–IV 33 (5 y)
Current study NBT +/- EBRT 31 I–III Two-channel 19.4 (6/31) 51.6 (5 y) 12.9 (4/31)
OS: overall survival; LDRB: low-dose-rate brachytherapy; HDRB: high-dose-rate brachytherapy; EBRT: external beam radiation therapy; NBT: neutron
brachytherapy.
Table 5 - Late toxicity.
Site Number of grade II complications (%)
Cystitis 3 (9.6%)
Rectum 1 (3.2%)
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